Literature DB >> 41240

Leukotriene C: a slow-reacting substance from murine mastocytoma cells.

R C Murphy, S Hammarström, B Samuelsson.   

Abstract

Murine mastocytoma cells treated with calcium ionophore A23187 produced a slow-reacting substance (SRS) that caused guinea pig ileum to contract. The response was reversed by the SRS antagonist FPL 55712. On the basis of isotope incorporation experiments, spectroscopy, and chemical degradations, the SRS was identified as a cysteine-containing derivative of 5-hydroxy-7,9,11,14-icosatetraenoic acid. This amino acid was attached in thioether linkage at C-6. The SRS is structurally related to previously identified epoxy and dihydroxy metabolites of arachidonic acid in leukocytes. A common feature is the presence of a conjugated triene, and the name "leukotriene" has been introduced to designate these compounds. Leukotriene A (5,6-epoxy-7,9,11,14-icosatetraenoic acid) is an intermediate in the formation of leukotriene B (5,12-dihydroxy-6,8,10,14-icosatetraenoic acid) and is proposed to be a precursor also of leukotriene C, which is the SRS identified here.

Entities:  

Keywords:  Abortifacient Agents--analysis; Abortion, Drug Induced; Abortion, Induced; Clinical Research; Family Planning; Fertility Control, Postconception; In Vitro; Research Methodology

Mesh:

Substances:

Year:  1979        PMID: 41240      PMCID: PMC411556          DOI: 10.1073/pnas.76.9.4275

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  On the structure of slow reacting substance of anaphylaxis: evidence of biosynthesis from arachidonic acid.

Authors:  M K Bach; J R Brashler; R R Gorman
Journal:  Prostaglandins       Date:  1977-07

2.  The release of 35-S-labelled material and SRS-A from immunologically challenged guinea-pig lungs.

Authors:  W Dawson; R L Lewis; R Tomlinson
Journal:  J Physiol       Date:  1975-05       Impact factor: 5.182

3.  Liberation of histamine and formation of lysocithin-like substances by cobra venom.

Authors:  W Feldberg; C H Kellaway
Journal:  J Physiol       Date:  1938-11-14       Impact factor: 5.182

4.  Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells.

Authors:  B A Jakschik; S Falkenhein; C W Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

Review 5.  Homeostasis of effector systems which can also be recruited for immunologic reactions.

Authors:  K F Austen
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

6.  Ionophore A 23187-induced production of slow reacting substance of anaphylaxis (SRS-A) by rat peritoneal cells in vitro: evidence for production by mononuclear cells.

Authors:  M K Bach; J R Brashler
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

7.  Release of slow reacting substance (SRS) from rat basophilic leukemia (RBL-1) cells.

Authors:  B A Jakschik; A Kulczycki; H H MacDonald; C W Parker
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

8.  Stimulated production of slow reacting substances by mercaptans from ionophore A 23187-induced mononuclear cells: mercaptan structure-activity studies.

Authors:  M K Bach; J R Brashler
Journal:  Life Sci       Date:  1978-11-20       Impact factor: 5.037

9.  Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids.

Authors:  P Borgeat; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

10.  Effects of modulators of arachidonic acid metabolism on the synthesis and release of slow-reacting substance of anaphylaxis.

Authors:  J F Burka; R J Flower
Journal:  Br J Pharmacol       Date:  1979-01       Impact factor: 8.739

View more
  177 in total

Review 1.  Regulation of expression of the 5-lipoxygenase pathway.

Authors:  T D Bigby
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Leukotriene receptor antagonist therapy.

Authors:  O J Dempsey
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 4.  Aspirin-induced asthma.

Authors:  L T Vaszar; D D Stevenson
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

5.  The mechanism for the contraction induced by leukotriene C4 in guinea-pig taenia coli.

Authors:  S Ieiri; J Nishimura; K Hirano; S Suita; H Kanaide
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

6.  Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma.

Authors:  N C Barnes; J C Pujet
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

Review 7.  Lysophospholipid acyltransferases and leukotriene biosynthesis: intersection of the Lands cycle and the arachidonate PI cycle.

Authors:  Robert C Murphy; Giancarlo Folco
Journal:  J Lipid Res       Date:  2019-01-03       Impact factor: 5.922

8.  Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations.

Authors:  Susanna L Lundström; Rohit Saluja; Mikael Adner; Jesper Z Haeggström; Gunnar Nilsson; Craig E Wheelock
Journal:  J Lipid Res       Date:  2012-10-03       Impact factor: 5.922

Review 9.  Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis.

Authors:  Bengü Cobanoğlu; Elina Toskala; Ahmet Ural; Cemal Cingi
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

10.  Effect of leucotrienes C4, D4, prostacyclin and thromboxane A2 on isolated human cerebral arteries.

Authors:  H von Holst; E Granström; S Hammarström; B Samuelsson; L Steiner
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.